CETIRIZINE HYDROCHLORIDE HIVES Drug Patent Profile
✉ Email this page to a colleague
When do Cetirizine Hydrochloride Hives patents expire, and when can generic versions of Cetirizine Hydrochloride Hives launch?
Cetirizine Hydrochloride Hives is a drug marketed by Dr Reddys Labs Ltd, Ipca Labs Ltd, Marksans Pharma, Mylan, Orbion Pharms, Perrigo R And D, Sun Pharm Inds Inc, Sun Pharm Inds Ltd, Unichem, Unique, Aurobindo Pharma Ltd, Bionpharma, Amneal Pharms Ny, Taro, and Torrent Pharms Llc. and is included in seventeen NDAs.
The generic ingredient in CETIRIZINE HYDROCHLORIDE HIVES is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-eight suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetirizine Hydrochloride Hives
A generic version of CETIRIZINE HYDROCHLORIDE HIVES was approved as cetirizine hydrochloride by PADAGIS US on June 17th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CETIRIZINE HYDROCHLORIDE HIVES?
- What are the global sales for CETIRIZINE HYDROCHLORIDE HIVES?
- What is Average Wholesale Price for CETIRIZINE HYDROCHLORIDE HIVES?
Summary for CETIRIZINE HYDROCHLORIDE HIVES
| US Patents: | 0 |
| Applicants: | 15 |
| NDAs: | 17 |
| Finished Product Suppliers / Packagers: | 74 |
| Raw Ingredient (Bulk) Api Vendors: | 119 |
| Clinical Trials: | 91 |
| Patent Applications: | 2,616 |
| DailyMed Link: | CETIRIZINE HYDROCHLORIDE HIVES at DailyMed |
Recent Clinical Trials for CETIRIZINE HYDROCHLORIDE HIVES
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| CURE Drug Repurposing Collaboratory (CDRC) | Phase 3 |
| Emory University | Phase 3 |
| Ruijin Hospital | Phase 1/Phase 2 |
Pharmacology for CETIRIZINE HYDROCHLORIDE HIVES
| Drug Class | Histamine-1 Receptor Antagonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for CETIRIZINE HYDROCHLORIDE HIVES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Torrent Pharms Llc | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | cetirizine hydrochloride | TABLET;ORAL | 079191-003 | Apr 15, 2010 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aurobindo Pharma Ltd | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | cetirizine hydrochloride | TABLET;ORAL | 090760-002 | Aug 5, 2015 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Torrent Pharms Llc | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | cetirizine hydrochloride | TABLET;ORAL | 079191-002 | Apr 15, 2010 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
